IMAGE

Fig. S4

ID
ZDB-IMAGE-150427-43
Source
Figures for Choe et al., 2015
Image
Figure Caption

Fig. S4 Parallel requirements for Pak2a and Alcama in pouch and CB cartilage development. (A) Double immunohistochemistry of pPAK-S143 (red) with Alcama (green) during maturation of the fifth pouch in wild types. As pouch development proceeds, Alcama becomes progressively enriched at sites of cell-cell contact while pPAK-S143 staining increases. Scale bar: 20 µm. (B) Immunohistochemistry shows that Efnb2a protein (green) is still present in her5:mCherryCAAX+ pouches (red cell membranes) in wnt4a-/- mutants and wild-type siblings. Efnb2a protein is also unaffected in surrounding neural-crest-derived cells (not labeled red) of wnt4a-/- mutants. (C) Fluorescent in situ hybridization shows ephb4a expression (green, arrowheads) in nascent her5:GFP+ pouches (labeled red by anti-GFP immunohistochemistry) in wnt4a mutants and wild-type siblings. Scale bar: 40 µm. (D) Double immunohistochemistry shows that pPAK-S143 staining (red) is reduced in the posterior pouches labeled by Alcama (green) of embryos expressing kinase-dead Ephb4a (nkx2.3:Gal4VP16; UAS:KD-Ephb4a) or dominantnegative Cdc42 (nkx2.3:Gal4VP16; UAS:DN-Cdc42) specifically in the endoderm. (E) Fluorescent in situ hybridization shows pak2a expression (green, arrowheads) in the her5:GFP+ pouches (labeled red by anti-GFP immunohistochemistry) in wild types, efnb2a-/-; efnb3b-MO embryos and nkx2.3:Pak2a; efnb2a-/-; efnb3b-MO embryos. (F) Immunohistochemistry shows E-cadherin protein (green) within pouches p4 and p5. In pak2a mutants or embryos expressing dominant-negative Pak2a specifically in the endoderm (nkx2.3:Gal4VP16; UAS:KD-Pak2a), E-cadherin staining is mildly reduced. Whereas injection of a low dose of alcama-MO (50 µM) into wild types causes no defects in E-cadherin localization, injection into pak2a mutants causes a greater reduction of Ecadherin staining (arrowhead) than seen in pak2a mutants alone. Scale bar: 20 µm. (G) Alcama immunohistochemistry reveals more severe defects in pouches in pak2a-/-; alcama-MO (50 µM) compound animals than in single pak2a mutants or alcama-MO animals. In addition, the nkx2.3:Pak2a transgene fails to rescue the pouch defects of efnb2a-/-; efnb3b-MO animals. Scale bar: 40 µm. (H) Alcian Blue staining reveals more severe losses of CB cartilages in pak2a-/-; alcama-MO (50 µM) compound animals compared with single pak2a mutants or alcama-MO animals. In addition, the nkx2.3:Pak2a transgene fails to rescue the CB cartilage defects of efnb2a-/-; efnb3b-MO animals. (I) Quantification of E-cadherin staining reduction. Data represent mean±s.e.m. P-values are shown. (J) Quantification of pouch and CB defects. Data represent mean±s.e.m. *** shows P<0.001 compared with pak2a mutants or alcama-MO animals. n.s., not significant.

Acknowledgments
This image is the copyrighted work of the attributed author or publisher, and ZFIN has permission only to display this image to its users. Additional permissions should be obtained from the applicable author or publisher of the image. Full text @ Development